Prolia, the No. 1 product in the domestic osteoporosis treatment market, has had its upper insurance price limit adjusted this month through price-volume agreement (PVA) negotiations. The drug underwent 4 PVA negotiations in total, which led to a price drop of nearly 30% from the initial price it received in October 2017 upon reimbursement.

According to industry sources on the 2nd, the upper limit for Prolia Prefilled Syringe (denosumab, Amgen Korea) was lowered from KRW 156,100 to KRW 154,700 from the 1st of this month under ‘Type B’ PVA negotiations with the National Health Insurance Service. The rate of reduction this time was -0.9%

Type B negotiations are applied when the expected